StockNews.AISignal intelligence
Regeneron Pharmaceuticals, Inc. · NASDAQ · Healthcare
Browse public REGN signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Bank of America Securities boosted Regeneron's price target to $1,030 while keeping a Buy rating, after REGN closed at $927.89 on Friday. The upgrade implies roughly 11% upside and reflects optimism for REGN's growth trajectory, potentially attracting near-term buying interest as investors reassess REGN's valuation against peers.
View signal analysisRegeneron is set to report Q3 results with consensus EPS of $16.19 on $4.56B revenue. The BARDA extension for Inmazeb strengthens US preparedness and could support near-term demand and pricing power for REGN's Ebola therapy. Upbeat analyst sentiment and higher price targets add optionality into the stock ahead of the print.
View signal analysisRegeneron extended its supply contract with a U.S. health authority to deliver additional doses of its Ebola treatment REGN-EB3 amid a growing outbreak in Africa. The move signals continued government demand and potential near-term revenue visibility, though no volumes or pricing were disclosed, limiting clarity on the upside.
View signal analysisRegeneron reported 84-week results from the OPTIMA Phase 3 trial of Pasatru in fibrodysplasia ossificans progressiva, showing sustained suppression of new heterotopic bone formation and fewer flare-ups. The data reinforce the 56-week endpoint and set the stage for the OPTIMA 2 pediatric trial later this year, potentially extending Pasatru's rare-disease footprint and Regeneron's growth optionality.
View signal analysisSanofi and Regeneron expanded their alliance to add REGN20423 and other long-acting antibodies, with a $1 billion upfront and up to $7 billion in milestones. The four Regeneron inventions will be jointly developed and shared 50/50 on profits, with Regeneron leading R&D and Sanofi handling commercialization; three assets are slated to enter clinical trials in 2027. Dupixent remains under the current profit-sharing arrangement, and Lunsekimig may join the collaboration after its phase 3 COPD readout.
View signal analysisNew conference data show Regeneron's experimental obesity drug, in combination with Novo Nordisk's semaglutide, reduces muscle-mass loss by 50% versus semaglutide alone. While early and not regulatory-approved, the result could strengthen REGN's obesity pipeline and attract potential collaboration or licensing interest if validated in later trials.
View signal analysis